Molecular Cancer

Call for Papers: New Thematic Series

For the third consecutive year, Molecular Cancer is excited to announce a new thematic series covering the general research area of Non-coding RNAs and RNA modifiers in cancer progression and cancer cells resistance to therapies. Of particular focus are original research papers reporting data from clinical trials or animal models. In addition to original research articles, we aim to publish letters to the Editor and comprehensive reviews.

All submitted manuscripts will undergo rigorous initial evaluation within 7 days, and then, when appropriate, will be sent out for external peer review to assess the suitability for publication. Submit here.

Submission deadline: December 1^st, 2019

Expected publication date: February 2020

Thematic Series Published in 2019: Microvesicles and Tumor Microenvironment in Cancer Development and Resistance to Therapies

This series of review articles aims to highlight significant findings and advances in our understanding of the role of the TME in cancer biology. The tumor microenvironment (TME) has an effect on tumor development, growth, and resistance to therapy. Continuous interactions and exchanges between tumor cells and the TME are involved in angiogenesis, tumor genetic diversity, immune escape, and metastasis.

Featured Article: Role of the NLRP3 inflammasome in cancer

In this review, Sahebkar et al. summarize the current knowledge on the contribution of the NLRP3 inflammasome on potential cancer promotion and therapy.

Thematic Series Published in 2018

Series of Review Articles: Oncogenic Signaling of Tyrosine Kinase in Cancer: Challenges and Therapeutic Opportunities

Content type: Research
| 16 September 2019

Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma

Authors: Jing Zhang, Shenglan Liu, Qianyun Ye and Jingxuan Pan
Content type: Review
| 16 September 2019

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations

Authors: Anqi Lin, Ting Wei, Hui Meng, Peng Luo and Jian Zhang
Content type: Review
| 16 September 2019

Functional roles of circular RNAs during epithelial-to-mesenchymal transition

Authors: Bing-Qing Shang, Min-Le Li, Hao-yu Quan, Ping-Fu Hou, Zhong-Wei Li, Su-Fang Chu, Jun-Nian Zheng and Jin Bai
Content type: Letter to the Editor
| 14 September 2019

Molecular characterization and clinical relevance of m⁶A regulators across 33 cancer types

Authors: Yongsheng Li, Jun Xiao, Jing Bai, Yi Tian, Yinwei Qu, Xiang Chen, Qi Wang, Xinhui Li, Yunpeng Zhang and Juan Xu
Content type: Review
| 13 September 2019

Biogenesis, functions and clinical significance of circRNAs in gastric cancer

Authors: Chan Shan, Yinfeng Zhang, Xiaodan Hao, Jinning Gao, Xinzhe Chen and Kun Wang

Most recent articles RSS

View all articles

Content type: Research
| 28 September 2014

Down regulation of Thrombospondin2 predicts poor prognosis in patients with gastric cancer

Authors: Ruochuan Sun, Jifeng Wu, Yuanyuan Chen, Mingdian Lu, Shangxin Zhang, Daru Lu and Yongxiang Li
Content type: Review
| 2 August 2013

The complexity of NF-κB signaling in inflammation and cancer

Authors: Bastian Hoesel and Johannes A Schmid
Content type: Research
| 9 October 2014

Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer

Authors: Donatella Del Bufalo, Marianna Desideri, Teresa De Luca, Marta Di Martile, Chiara Gabellini, Valentina Monica, Simone Busso, Adriana Eramo, Ruggero De Maria, Michele Milella and Daniela Trisciuoglio
Content type: Research
| 22 July 2010

Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition

Authors: María M Caffarel, Clara Andradas, Emilia Mira, Eduardo Pérez-Gómez, Camilla Cerutti, Gema Moreno-Bueno, Juana M Flores, Isabel García-Real, José Palacios, Santos Mañes, Manuel Guzmán and Cristina Sánchez
Content type: Review
| 29 May 2014

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress

Authors: Mildred Felder, Arvinder Kapur, Jesus Gonzalez-Bosquet, Sachi Horibata, Joseph Heintz, Ralph Albrecht, Lucas Fass, Justanjyot Kaur, Kevin Hu, Hadi Shojaei, Rebecca J Whelan and Manish S Patankar

Most accessed articles RSS

View all articles

Editor-in-Chief

Christophe Nicot, Kansas University Medical Center, USA

Aims and scope

Molecular Cancer is an open access, peer-reviewed journal interested in attracting high-quality original research and reviews that present or highlight significant advances in all areas of cancer and related biomedical science.

Molecular Cancer

Call for Papers: New Thematic Series

Thematic Series Published in 2019: Microvesicles and Tumor Microenvironment in Cancer Development and Resistance to Therapies

Featured Article: Role of the NLRP3 inflammasome in cancer

Thematic Series Published in 2018

Articles

Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations

Functional roles of circular RNAs during epithelial-to-mesenchymal transition

Molecular characterization and clinical relevance of m⁶A regulators across 33 cancer types

Biogenesis, functions and clinical significance of circRNAs in gastric cancer

Down regulation of Thrombospondin2 predicts poor prognosis in patients with gastric cancer

The complexity of NF-κB signaling in inflammation and cancer

Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer

Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress

Editor-in-Chief

Aims and scope

Follow

Annual Journal Metrics

Molecular Cancer

Contact us